The platform will enable Bayer to more effectively utilize genomics data in oncology research, such utilization to be conducted in compliance with respective patients' informed consent and applicable laws and regulations.
"Genomics data is increasingly used both in pre-clinical and clinical research, but lacks software tools that can be adapted to various research environments. Our flexible platform and know-how in designing software for demanding bioinformatics environments will be tailored to meet the needs of oncology research at Bayer HealthCare Pharmaceuticals,” says Tommi Pisto, CEO of MediSapiens.
"Our core knowledge is to combine bioinformatics and web software. Experience in building and managing the world's largest unified gene expression database for researchers' needs has been invaluable in creating the flexible and scalable genomics platform we now put into use for this project,” adds Sami Kilpinen, PhD, CSO of MediSapiens .